Share on StockTwits

Consort Medical plc (LON:CSRT)‘s stock had its “buy” rating restated by research analysts at Westhouse Securities in a report released on Friday. They currently have a GBX 1,100 ($18.44) price target on the stock. Westhouse Securities’ target price would indicate a potential upside of 25.71% from the stock’s previous close.

Consort Medical plc (LON:CSRT) opened at 873.4999 on Friday. Consort Medical plc has a 1-year low of GBX 733.00 and a 1-year high of GBX 1113.00. The stock has a 50-day moving average of GBX 884.1 and a 200-day moving average of GBX 942.7. The company’s market cap is £251.3 million.

A number of other analysts have also recently weighed in on CSRT. Analysts at Goldman Sachs reiterated a “strong-buy” rating on shares of Consort Medical plc in a research note on Thursday, May 15th. They now have a GBX 590 ($9.89) price target on the stock. Separately, analysts at Canaccord Genuity reiterated a “buy” rating on shares of Consort Medical plc in a research note on Tuesday, May 13th. They now have a GBX 1,044 ($17.50) price target on the stock. Finally, analysts at FinnCap reiterated a “sell” rating on shares of Consort Medical plc in a research note on Tuesday, May 13th. They now have a GBX 690 ($11.57) price target on the stock. One analyst has rated the stock with a sell rating, five have issued a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of “Hold” and an average price target of GBX 934.33 ($15.66).

Consort Medical plc is a healthcare company focused on medical technologies. The principal activities of the Company are the design, development and manufacture of specialty medical drug delivery devices and services to the pharmaceutical industry through its Bespak Division and disposable airway management products for critical care settings in hospitals and pre-hospital settings through its King Systems Division.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.